AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone.

Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).

REALIZE-K is a phase 4 double-blind, placebo-controlled, randomized-withdrawal, parallel-group study aiming to evaluate the efficacy of sodium zirconium cyclosilicate (SZC) in managing potassium levels in patients with heart failure with reduced ejection fraction whilst on spironolactone ≥25 mg daily. 366 patients were enrolled in this study of three phases, including a screening period, a 4-6 week open-label run-in phase optimizing SZC and spironolactone, and a 6-month treatment phase.

Recorded on-site at AHA Conference 2024, Chicago.

Editors: Jordan Rance and Yazmin Sadik.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.